Schering-Plough Corp. (SGP.N: Quote, Profile, Research) said on Monday that it had begun late-stage trials of an experimental HIV drug that showed promising effectiveness in earlier studies but aroused safety concerns because of cancers seen in some patients taking it.
The U.S. drugmaker said it had begun two Phase III trials of vicriviroc, a once-daily tablet that works through the same mechanism as Pfizer Inc's (PFE.N: Quote, Profile, Research) recently approved Selzentry, or maraviroc. Both potentially can help patients whose virus has become resistant to earlier HIV treatments.
read more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment